Acelyrin, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLRN research report →
Companywww.acelyrin.com
Acelyrin, Inc. , a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
- CEO
- Mina Kim
- IPO
- 2023
- Employees
- 83
- HQ
- Agoura Hills, CA, US
Price Chart
Valuation
- Market Cap
- $229.17M
- P/E
- -1.70
- P/S
- 670.07
- P/B
- 0.56
- EV/EBITDA
- -2.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 50.00%
- Op Margin
- -42563.45%
- Net Margin
- -39268.13%
- ROE
- -31.03%
- ROIC
- -35.23%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-248,226,000 · 34.96%
- EPS
- $-2.50 · 53.96%
- Op Income
- $-316,258,000
- FCF YoY
- -67.68%
Performance & Tape
- 52W High
- $7.25
- 52W Low
- $1.84
- 50D MA
- $2.40
- 200D MA
- $3.55
- Beta
- 1.09
- Avg Volume
- 997.03K
Get TickerSpark's AI analysis on SLRN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 21, 25 | AyurMaya Capital Management Company, LP | sell | 9,334,735 |
| May 21, 25 | Kim Mina | other | 89,526 |
| May 21, 25 | Kim Mina | sell | 190,114 |
| May 21, 25 | Kim Mina | sell | 770,833 |
| May 21, 25 | Kim Mina | sell | 1,195,856 |
| May 21, 25 | Kim Mina | sell | 85,226 |
| May 21, 25 | Kim Mina | sell | 362,719 |
| May 21, 25 | COZADD BRUCE C | sell | 92,158 |
| May 21, 25 | COZADD BRUCE C | sell | 183,434 |
| May 21, 25 | COZADD BRUCE C | sell | 23,243 |
Our SLRN Coverage
We haven't published any research on SLRN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SLRN Report →